Ibudilast has [[bronchodilator]], [[vasodilator]]<ref>{{cite journal | last1 = Kishi | first1 = Y | last2 = Ohta | first2 = S | last3 = Kasuya | first3 = N | last4 = Sakita | first4 = S | last5 = Ashikaga | first5 = T | last6 = Isobe | first6 = M | date = Fall 2001 | title = Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall | url = | journal = Cardiovascular Drug Reviews | volume = 19 | issue = 3| pages = 215–25 }}</ref> and [[Neuroprotection|neuroprotective]] effects,<ref>Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, Jacob Linder, Suzumura A. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. ''Neuropharmacology''. 2004 Mar;46(3):404-11.</ref><ref>{{cite journal | last1 = Yoshioka | first1 = M | last2 = Suda | first2 = N | last3 = Mori | first3 = K | last4 = Ueno | first4 = K | last5 = Itoh | first5 = Y | last6 = Togashi | first6 = H | last7 = Matsumoto | first7 = M | date = Apr 2002 | title = Effects of ibudilast on hippocampal long-term potentiation and passive avoidance responses in rats with transient cerebral ischemia | url = | journal = Pharmacological Research | volume = 45 | issue = 4| pages = 305–11 | doi=10.1006/phrs.2002.0949}}</ref> and is mainly used in the treatment of [[asthma]] and [[stroke]].<ref>{{cite journal | last1 = Wakita | first1 = H | last2 = Tomimoto | first2 = H | last3 = Akiguchi | first3 = I | last4 = Lin | first4 = JX | last5 = Ihara | first5 = M | last6 = Ohtani | first6 = R | last7 = Shibata | first7 = M | date = Nov 2003 | title = Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat | url = | journal = Brain Research | volume = 992 | issue = 1| pages = 53–9 | doi=10.1016/j.brainres.2003.08.028}}</ref> It inhibits [[platelet]] aggregation,<ref>{{cite journal | last1 = Rile | first1 = G | last2 = Yatomi | first2 = Y | last3 = Qi | first3 = R | last4 = Satoh | first4 = K | last5 = Ozaki | first5 = Y | date = May 2001 | title = Potentiation of ibudilast inhibition of platelet aggregation in the presence of endothelial cells | url = | journal = [[Thrombosis Research]] | volume = 102 | issue = 3| pages = 239–46 | doi=10.1016/s0049-3848(01)00258-4}}</ref> and may also be useful in the treatment of [[multiple sclerosis]].<ref>{{cite journal | last1 = Feng | first1 = J | last2 = Misu | first2 = T | last3 = Fujihara | first3 = K | last4 = Sakoda | first4 = S | last5 = Nakatsuji | first5 = Y | last6 = Fukaura | first6 = H | last7 = Kikuchi | first7 = S | last8 = Tashiro | first8 = K | last9 = Suzumura | first9 = A | last10 = Ishii | first10 = N | last11 = Sugamura | first11 = K | last12 = Nakashima | first12 = I | last13 = Itoyama | first13 = Y | date = Oct 2004 | title = Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis | url = | journal = Multiple Sclerosis | volume = 10 | issue = 5| pages = 494–8 | doi=10.1191/1352458504ms1070oa}}</ref>

 
Ibudilast is listed as being an [[Receptor antagonist|antagonist]] at the [[toll-like receptor]] 4 ([[TLR4]]).<ref>{{Cite journal|last=Jia|first=Ze-jun|last2=Wu|first2=Fei-xiang|last3=Huang|first3=Qing-hai|last4=Liu|first4=Jian-min|date=2012-04-01|title=[Toll-like receptor 4: the potential therapeutic target for neuropathic pain]|journal=Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae|volume=34|issue=2|pages=168–173|doi=10.3881/j.issn.1000-503X.2012.02.013|issn=1000-503X|pmid=22776604}}</ref> This likely play an immense part in its effect, specifically its synergy with opioid drugs, its [[anti-inflammatory]] effect, and its own [[Analgesic|painkilling]] effect.<ref>{{Cite journal|last=Hutchinson|first=Mark R.|last2=Zhang|first2=Yingning|last3=Shridhar|first3=Mitesh|last4=Evans|first4=John H.|last5=Buchanan|first5=Madison M.|last6=Zhao|first6=Tina X.|last7=Slivka|first7=Peter F.|last8=Coats|first8=Benjamen D.|last9=Rezvani|first9=Niloofar|date=2010-01-01|title=Evidence that opioids may have toll like receptor 4 and MD-2 effects|journal=Brain, behavior, and immunity|volume=24|issue=1|pages=83–95|doi=10.1016/j.bbi.2009.08.004|issn=0889-1591|pmc=2788078|pmid=19679181}}</ref> It is unknown if the PDE4-inhibiting properties [[Drug synergy|potentiate]] the effects of TLR4 inactivation and/or vice versa, despite that some of their effects are shared, such as [[inflammation]] reducing properties.<ref>{{Cite journal|last=Jin|first=S.-L. Catherine|last2=Ding|first2=Shiau-Li|last3=Lin|first3=Shih-Chang|date=2012-06-01|title=Phosphodiesterase 4 and its inhibitors in inflammatory diseases|journal=Chang Gung Medical Journal|volume=35|issue=3|pages=197–210|issn=2309-835X|pmid=22735051|doi=10.4103/2319-4170.106152}}</ref>
